Autonomix Medical to Acquire Neuro-Stim Technologies

TL;DR

Autonomix buying Neuro-Stim to boost its medical device game.

AI Summary

Autonomix Medical, Inc. announced on November 4, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Neuro-Stim Technologies, LLC. The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions. This strategic move aims to expand Autonomix Medical's product portfolio and market reach in the neuro-modulation space.

Why It Matters

This acquisition could significantly enhance Autonomix Medical's position in the medical device market by integrating Neuro-Stim Technologies' offerings, potentially leading to new revenue streams and market share growth.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies, which could impact Autonomix Medical's financial performance.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• Neuro-Stim Technologies, LLC (company) — Target company for acquisition
• November 4, 2024 (date) — Date of the agreement
• first quarter of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark

Filing Documents

• amix20241104_8k.htm (8-K) — 24KB
• autonomix01.jpg (GRAPHIC) — 4KB
• 0001437749-24-033163.txt ( ) — 167KB
• amix-20241104.xsd (EX-101.SCH) — 3KB
• amix-20241104_def.xml (EX-101.DEF) — 12KB
• amix-20241104_lab.xml (EX-101.LAB) — 15KB
• amix-20241104_pre.xml (EX-101.PRE) — 12KB
• amix20241104_8k_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On October 24, 2024, Autonomix Medical, Inc. (the "Company") completed a one-for-twenty reverse stock split of its common stock. In connection with the approval of the reverse stock split, the Company agreed that no fractional shares will be issued in connection with the reverse stock split and that it would issue one full share of the post-reverse stock split common stock to any stockholder who would have been entitled to receive a fractional share as a result of the process. On November 1, 2024, the Company received notice from DTCC on behalf of the brokerage firms that hold the shares of Company common stock held in "street name" that in connection with the foregoing rounding of shares the Company would need to issue 271,846 shares of common stock.Prior to the Company's required announcement regarding the reverse stock split on October 22, 2024, the Company estimates there were approximately 4,800 shareholders of record. The Company does not believe the number of shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar occurrences in recent months for other companies completing a reverse stock split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does not intend to issue any shares in connection with the fractional shares being requested. The Company may face potential liability for its failure to issue the shares of common stock if it is determined that it is required to issue such shares. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: November 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR